{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"Serious and non-serious adverse events were assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.","groups":[{"description":"Patients receiving second allogeneic bone marrow transplant on this study.","id":"OG000","title":"Transplant Recipient - 2nd Bone Marrow Transplant"}],"paramType":"NUMBER","populationDescription":"Only the patients in the SG4 group who had a 2nd BMT had a primary endpoint of toxicity requiring leuprolide AE reporting.","reportingStatus":"POSTED","timeFrame":"12 months after second BMT","title":"Number of Adverse Events Related to Study Drug Experienced by Participants After Second Bone Marrow Transplant (BMT)","type":"PRIMARY","unitOfMeasure":"Adverse Events"}